Advanced or metastatic gastroesophageal junction carcinoma

Clinical trials for Advanced or metastatic gastroesophageal junction carcinoma explained in plain language.

Never miss a new study

Get alerted when new Advanced or metastatic gastroesophageal junction carcinoma trials appear

Sign up with your email to follow new studies for Advanced or metastatic gastroesophageal junction carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

A phase II clinical study to evaluate the efficacy and safety of MRG003 in EGFR-Positive, HER2-Negative advanced gastric cancer.

Stopped early

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with EGFR-positive, HER2-negative, inoperable locally advanced or metastatic gastric cancer.

Matched conditions: ADVANCED OR METASTATIC GASTROESOPHAGEAL JUNCTION CARCINOMA

Phase 2 • Sponsor: Lepu Biopharma Co., Ltd.

Last updated Sep 09, 2026 17:00 UTC

Advanced or metastatic gastroesophageal junction carcinoma

Get alerted when new Advanced or metastatic gastroesophageal junction carcinoma trials appear

A phase II clinical study to evaluate the efficacy and safety of MRG003 in EGFR-Positive, HER2-Negative advanced gastric cancer.